🎉30 $10B+ US Stocks Hit New Highs:AVGO, MS, GS Lead & Uptrend Drivers
As of Monday's market close, $Dow Jones(.DJI)$ dropped 0.4%, $S&P 500(.SPX)$ slipped about 0.3%, and $NASDAQ(.IXIC)$ edged down 0.1%, showed bearish performance. Data from TradingView shows that 30 companies with a market cap of over $10 billion have reached new highs.Focus on Federal Reserve policy: With the Fed meeting approaching this week, investors grew cautious. Many expect a rate cut — the odds priced in by traders remain very high.Treasury yields rose, bond market jitters: Continued selling pressure in U.S. Treasuries pushed long‑term yields higher, putting pressure on equity valuations.Market uncertainty dominates until the Fed decision: With corpor
I share the results of this weekly scan on every end of the week session (Saturday/Sunday) because my primary focus each week starts with this names. Let me dissect down why we should keep an eye on these leaders for opportunities in both swing and positional trading:1. Strongest Stocks In Growth Rate: These stocks have latest quarterly sales and EPS growth exceeding 25% year-over-year.2. Technical Filter: Only a 50-day MA filter is applied. If the fundamental strength leads to tradable price action, let the stock set up naturally. I also imposed a volatility 1M 3% filter for 2 reason, 1) to remove stocks that already with announced merger & acquisitions eg. $SWAV $NVEI will appear, 2) clear linearity for tradable price action3. Industry Group Sorting: Purpose is to identify any domina
Option Movers | This Trump Media Call Soars 1038% in One Day; Riot Platforms Sees Bullish Sentiment
Market OverviewThe Nasdaq fell on Monday, while the benchmark S&P 500 bounced off a two-month low and eked out a slight gain as U.S. Treasury yields stayed elevated with investors dialing back expectations on the pace of rate cuts from the Federal Reserve.Regarding the options market, a total volume of 46,299,103 contracts was traded.Top 10 Option VolumesTop 10: $Nvidia(NVDA)$, $Tesla(TSLA)$, $CBOE Volatility Index(VIX)$, $Apple(AAPL)$, $Palantir(PLTR)$, $AMD(AMD)$, $Trump Media(DJT)$,
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.